PTAB Upholds Much Of Cannabis Epilepsy Treatment Patent

By Matthew Bultman (January 7, 2019, 7:45 PM EST) -- The Patent Trial and Appeal Board upheld much of a patent that involves the use of cannabinoids to treat epilepsy, handing a partial win to a unit of GW Pharmaceuticals PLC, a U.K. company known for its marijuana-derived medicines.

In a decision Thursday, the board found that Insys Development Co. Inc. had shown in inter partes review that two challenged claims in GW Pharma Ltd.'s patent would have been obvious. But the board said the company failed to establish that close to a dozen other claims were invalid.

The patent is directed to the use of marijuana components such as nonpsychoactive cannabidiol,...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!